Inventor
Ruth R. Wexler
Inventor
Wilmington, DE, US
Overview
Patents· 30 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds60%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium6%
A61KPreparations for medical, dental or toiletry purposes4%
PatentTitleYear
11,053,247Pyrimidinones as factor XIA inhibitors202110,336,754Pyrimidinones as factor XIa inhibitors201910,273,236Macrocyclic factor XIa inhibitors bearing heterocyclic groups20199,777,001'Macrocycles with aromatic P2′ groups as factor xia inhibitors'20179,453,018'Pyrimidinones as factor XIa inhibitors'20167,109,339'Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists'20066,951,872'Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors'20056,949,550'Substituted amino methyl factor Xa inhibitors'20056,878,710'Bicyclic inhibitors of factor Xa'20056,790,845'Fused heterocyclic inhibitors of factor Xa'20046,710,058'Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors'20046,689,770'Aryl sulfonyls as factor Xa inhibitors'20046,602,871'Thrombin or factor Xa inhibitors'20036,426,346'6-membered aromatics as factor Xa inhibitors'20026,403,583'Thrombin or factor Xa inhibitors'20026,399,644'Aryl sulfonyls as factor XA inhibitors'20026,365,587'Substituted aryl hydroxamic acids as metalloproteinase inhibitors'20026,268,379'Substituted aryl hydroxamic acids as metalloproteinase inhibitors'20016,060,491'6-membered aromatics as factor Xa inhibitors'20006,043,257'Amidinoindoles, amidinoazoles, and analogs thereof'20005,886,191'Amidinoindoles, amidinoazoles, and analogs thereof'19995,478,830'Fused-ring heterocycles for the treatment of atherosclerosis'19955,318,984'Imidazoles for the treatment of atherosclerosis'19945,310,748'Imidazoles for the treatment of atherosclerosis'19945,290,801'Benzimidazoles for the treatment of atherosclerosis'19945,166,214'Use of imidazoles for the treatment of atherosclerosis'19925,091,390'Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs'19924,868,181'1,4-dihydropyridine derivatives with calcium agonist and alpha.sub.1 -antagonist activity'19894,632,930'Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives'19864,576,958'Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives'1986Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1986–2000Patents assigned to DU PONT (5)· patent assignee history
1986–2002Based in Wilmington, DE, US· patent location history
1992–1995Patents assigned to DU PONT MERCK PHARMA (5)· patent assignee history
1999–2001Patents assigned to DU PONT PHARM CO (3)· patent assignee history
2002–2005Patents assigned to BRISTOL MYERS SQUIBB PHARMA CO (7)· patent assignee history
2002–2005Based in Chadds Ford, PA, US· patent location history
2004–2005Based in Chaddsford, PA, US· patent location history
2005–2021Patents assigned to BRISTOL MYERS SQUIBB CO (7)· patent assignee history
2006–2021Based in Belle Mead, NJ, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BRISTOL MYERS SQUIBB CO | 7 | 2005–2021 |
| BRISTOL MYERS SQUIBB PHARMA CO | 7 | 2002–2005 |
| DU PONT | 5 | 1986–2000 |
| DU PONT MERCK PHARMA | 5 | 1992–1995 |
| DU PONT PHARM CO | 3 | 1999–2001 |
Locations
| Location | Patents | Span |
|---|---|---|
| Wilmington, Delaware, US | 15 | 1986–2002 |
| Chadds Ford, Pennsylvania, US | 7 | 2002–2005 |
| Belle Mead, New Jersey, US | 6 | 2006–2021 |
| Chaddsford, Pennsylvania, US | 2 | 2004–2005 |